E. et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297, 1465–1477 (2007). Article CAS PubMed Google Scholar Reid, I. R. et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in...
the cause for symptoms in postmenopausal women is less likely to be vulvovaginal candidiasis, and the impact of ageing means that other diagnoses must be considered. Friedrich, one of the founders of the International Society for the Study of Vulvovaginal Disease, wrote...
The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, ... OBJECTIVE: Most observational studies suggest that postmenopausal women taking hormone replacement therapy have a reduced risk of radiographic knee...
several therapeutic interventions in osteo- porosis, hormone replacement therapy (HRT, estrogen plus progestins) or estrogen replacement therapy (ERT) have traditionally been seen as the gold standard method in postmenopausal women for many years, as well as for the management of menopausal symptoms....
Our study findings add to the body of literature that previously examined the association between dyslipidemia or imbalance in Lipid profile and breast cancer. The decision of the lipid acquisition pathway may also be influenced by additional elements, such as central obesity. According to recent ...
However, an imbalance in calcium and protein intake was observed between the high-dose group and placebo group, with the latter having greater intakes of both of these nutrients. This may have affected the longitudinal changes in bone parameters since it is well established that increa...
Osteoporosis is a bone disease due to an imbalance of bone remodeling, which causes bone resorption to exceed bone formation and leads to loss of bone density and regression of the bone microstructure [2]. In elder women, the most common risk factor of osteoporosis is the lack of estrogen ...
Q5.6. What Is the Role of Estrogen and Menopausal Hormone Therapy in Treatment of Postmenopausal Osteoporosis? Although once considered the treatment of choice for postmenopausal osteoporosis, estrogen was never specifically approved for this use. Estrogen is approved by the FDA for prevention of postme...
Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. Int J Mol Sci. 2022;23:1376. (This article provides an overview of the molecular mechanisms, risk factors for estrogen deficiency and glucocorticoid overuse-related ...
Thus, drospirenone is a unique progestogen that confers the additional benefit of BP reduction, an effect that could lead to potential benefit with respect to some cardiovascular risk concerns in women taking hormone therapy.doi:10.2165/00002512-200724060-00002Mallareddy, Madhavi...